Future Markets Research Releases Commentary on NurExone Biologic Inc, An Emerging Leader in The Exosomal Treatment of Spinal Cord Injury
02 Octubre 2022 - 5:50PM
Business Wire
The Future Markets Research Tank (FMRT) is proud to release
market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an
innovative biotechnology company poised to disrupt the spinal cord
injury treatment industry and the exosome research landscape. To
read the full report click here, or follow the link:
https://bit.ly/3UW9TzC
Key Insights:
- Each year, hundreds of thousands of people suffer from spinal
cord injury. In addition, poor medical care and the lack of
availability of effective treatments contribute to an increase in
SCI patient mortality and disability.
- With rising numbers of workplace accidents, road accidents, and
other medical conditions, the global SCI therapeutics market is
anticipated to grow at a Compound annual growth rate (CAGR) of
17.84% to reach US$9.61 billion by 2028. There is a pressing need
to create novel therapeutics to treat SCI due to the exorbitant
cost of spinal surgery procedures and related healthcare
costs.
- In parallel, the global exosome market is estimated to grow at
a CAGR of more than 34% between 2022 and 2030, reaching a market
value of around USD 2,273 million by 20303
- NurExone Biologic is an exciting company that sits at the
forefront of these two fast growing arenas. With their unique
ExoTherapies, NurExone is making significant advancements towards
becoming a market leader in exosome-based treatment for acute
spinal cord injuries. As the company grows, it has announced
numerous strategic initiatives, such as plans to expand its
intellectual property portfolio and partnerships for advanced
research.
- Moreover, positive preliminary findings prove the company's
potential and distinguish itself as an emerging exosome leader with
an intriguing biotechnology portfolio and offering. As the company
continues innovating and achieving meaningful milestones, they are
well positioned to become a leading biotech company and central
player in both the exosome and the spinal cord treatment
arenas.
To read the full report click here, or follow
the link: https://bit.ly/3UW9TzC
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221002005077/en/
Ronald Kaufman Future Markets Research Tank (FMRT)
ronald@futuremarketsresearch.com